- Email: [email protected]
Molecular Target Treatment of Metastatic Renal Cell Carcinoma
Annals of Oncology 25 (Supplement 5): v14–v16, 2014 doi:10.1093/annonc/mdu407.3
Educational Lecture EL3
MOLECULAR TARGET TREATMENT OF METASTATIC RENAL CELL CARCINOMA
abstracts
In Japan, six molecularly-targeted drugs: four vascular endothelial growth factor (VEGF) pathway inhibitors and two mammalian target of rapamycin (mTOR)
© The Author 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: [email protected].
Downloaded from https://academic.oup.com/annonc/article-abstract/25/suppl_5/v14/2240142 by guest on 24 October 2019
Keita Uchino Kyushu Medical Center, Department of Medical Oncology
inhibitors have open the way for improvements in clinical outcome of metastatic renal cell carcinoma (mRCC) patients. Many evidences from pivotal clinical trials have provided treatment strategy based on the biology of mRCC, the patient characteristic features and so on. In clinical practice, medical oncologists and urologists have been required to select the optimal therapy sequence considering including the other factors: toxicity profiles, comorbidities and patient preference. Optimal managements of various adverse events have been required, so multidisciplinary team of physicians, nurses, pharmacists and other professionals is necessary to practice molecular target treatment of mRCC to maximize clinical results for patients. For further improvement of treatment of mRCC patients, development in the following fields is expected: drugs targeting pathways other than VEGF/mTOR pathways, immunotherapeutic drugs, identification of predictive biomarkers and progress of molecular imaging, and further improvement of adverse events management. This lecture will provide an overview of current and emerging systemic treatments of mRCC.
Educational Lecture EL3
MOLECULAR TARGET TREATMENT OF METASTATIC RENAL CELL CARCINOMA
abstracts
In Japan, six molecularly-targeted drugs: four vascular endothelial growth factor (VEGF) pathway inhibitors and two mammalian target of rapamycin (mTOR)
© The Author 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: [email protected].
Downloaded from https://academic.oup.com/annonc/article-abstract/25/suppl_5/v14/2240142 by guest on 24 October 2019
Keita Uchino Kyushu Medical Center, Department of Medical Oncology
inhibitors have open the way for improvements in clinical outcome of metastatic renal cell carcinoma (mRCC) patients. Many evidences from pivotal clinical trials have provided treatment strategy based on the biology of mRCC, the patient characteristic features and so on. In clinical practice, medical oncologists and urologists have been required to select the optimal therapy sequence considering including the other factors: toxicity profiles, comorbidities and patient preference. Optimal managements of various adverse events have been required, so multidisciplinary team of physicians, nurses, pharmacists and other professionals is necessary to practice molecular target treatment of mRCC to maximize clinical results for patients. For further improvement of treatment of mRCC patients, development in the following fields is expected: drugs targeting pathways other than VEGF/mTOR pathways, immunotherapeutic drugs, identification of predictive biomarkers and progress of molecular imaging, and further improvement of adverse events management. This lecture will provide an overview of current and emerging systemic treatments of mRCC.